We are a worldwide speciality and branded pharmaceutical business with our headquarters in Durban, South Africa. Our mission is to improve the health of people all over the globe by providing medications that are of the highest quality and are also affordable.
What does Aspen Pharmacare do?
Aspen is a global speciality and branded multinational pharmaceutical firm that has been around for 170 years. The company has a presence in both developing and established countries across the world. We promote the health of patients in over 150 countries through the distribution of medications that are of a high quality and are not prohibitively expensive.
- Our company has around 9,100 people working in 69 established offices spread across more than 50 nations.
- Through its core business sectors, Aspen concentrates on the marketing and manufacture of a comprehensive selection of post-patent, branded pharmaceuticals as well as local products, with the goal of catering to both the hospital and consumer markets.
Manufacturing and Commercial Pharmaceuticals, which are broken down into Regional Brands and Sterile Focus Brands, are two of our most important business sectors. Our production capabilities extend to a wide range of product categories, which include steriles, oral solid dosage, liquids, semi-solids, biologicals, and active pharmaceutical components.
What does Aspen Pharmacare make?
Aspen is a leading global supplier in the Anaesthetics category (House of Anesthesia), outside of the United States of America, due to the breadth and depth of our product offering, which includes not only general anesthetics and muscle relaxants but also a number of local anesthetics, among which are topical agents.
What products does Aspen make?
Our primary concentration is on developing markets, particularly those in which we already have solid positions on the ground. The possibility of organic development for this portfolio resides in the expansion of volume within branded prescription drugs, over-the-counter franchises, and consumer brand names. Important labels.
| Brand | Type of anaesthetic |
|---|---|
| Naropin | Regional |
| Ultiva | General |
| Xylocaine | Regional |
Who owns Aspen Pharmacare?
Stephen Bradley Saad is a South African billionaire businessman who was born in June 1964. He is the founder and chief executive officer of Aspen Pharmacare (JSE: APN), which is the largest producer of generic medicines in Africa. Saad has been in the pharmaceutical industry for more than four decades.
| Stephen Saad | |
|---|---|
| Alma mater | University of Natal |
| Occupation | Businessman |
What kind of company is Aspen?
ABOUT ASPEN We are a worldwide speciality and branded pharmaceutical business with our headquarters in Durban, South Africa. Our mission is to improve the health of people all over the globe by providing medications that are of the highest quality and are also affordable.
Is Aspen a generic company?
As of the year 2022, Aspen is a multinational pharmaceutical corporation that specializes in both the production of generic pharmaceuticals and speciality drugs. The majority of Aspen’s income comes from the sale of commercial drugs (74%) while the production of drugs accounts for just 26%.
Why do you want to work for Aspen?
Aspen is a vibrant organization that was founded on the power of its entrepreneurs and the imaginations of those who think forward. We look for high-performing individuals that are enthusiastic about their chosen field of work and have the ambition to go above and beyond what is expected of them.
Why is Aspen share price dropping?
Aspen Pharmacare, the largest pharmaceutical maker in South Africa, said on Wednesday that it will resume paying dividends to its shareholders. This comes after the company successfully reduced its debt to levels that are far lower than those needed by its lenders.
- According to what was stated, the company would provide its shareholders a dividend equal to 262 cents per share, and it will evaluate whether or not to make additional payments on an annual basis.
- Due to the enormous amount of debt that it accumulated as a result of a series of acquisitions that diversified the firm beyond its original generics basis, Aspen decided in 2019 to do away with dividend payments.
This decision was made well in advance of the coronavirus crisis. It continued to withhold dividends throughout the year 2020 as it refocused the business and sold assets to reduce its debt. Along with businesses operating in a diverse range of industries, it was attempting to preserve capital in the face of the unpredictability that the coronavirus pandemic brought to the business world.
The share price of Aspen has decreased by about half of its value over the previous five years. This decline may be largely attributed to market skepticism regarding the magnitude of the debt that the company incurred during its frenzy of acquisitions. Late in 2019, when investor fears over the business’s debt were at an all-time high, the stock dropped to a low of around R65, but it has since started to recover as the company has begun to cut its borrowings.
The price of an Aspen share was R190.51 at the day’s end on Wednesday. During the fiscal year that ended on June 30, Aspen’s net debt decreased by more than half, going from R35.2 billion the year before to R16.3 billion. According to a statement released by the company after the market had closed, the reduction in borrowings was brought about by the sale of Aspen’s European thrombosis business, robust operating cash flows, and a stronger rand in comparison to the euro and the Australian dollar at the end of the year.
As a consequence of this, Aspen’s leverage ratio was 1.74 times at the end of the year, which was significantly lower than the 3.5 times that was needed by its lenders. Lenders evaluate a company’s ability to service its debt by looking at its leverage ratio. This ratio measures how effectively a company’s earnings can pay its debt.
Aspen reported a 12% gain in sales, which brought the total to R37.8 billion, up from R33.7 billion the previous year. Normalized headline profits per share increased by 10% to R13.10, compared to R11.94 the year before, in part owing to lower financing expenses.
- This profit metric is used in South Africa and eliminates some one-off elements from the calculation in order to ensure more accurate results.
- The normalized profits before interest, tax, depreciation, and amortisation grew by 3% to R9.9 billion as a result of the largely offsetting effects of limiting operational expenditures on the lower gross profit and reduced operating income.
Aspen stated that it had been able to provide a reliable supply of its medicines and products despite the challenges thrown up by Covid-19. However, sales of its specialist anaesthetic products had been volatile due to the fact that elective procedures had been postponed when infections surged, even as demand for products used to treat Covid-19 patients rose when the number of cases mounted.
- According to Aspen, the firm is now in a position to play a key role in the provision of Covid-19 vaccines for Africa as a result of the investment the company made in its sterile production facility in Gqeberha.
- In November of 2020, Aspen successfully negotiated a deal with Johnson & Johnson, the makers of the Covid-19 vaccine, to develop, fill, and complete its single-shot injection.
“Aspen is confident that the present conversations between J&J and Aspen, including a prospective license for Africa, might make a major contribution to increasing equitable Covid-vaccine access for the continent,” the company stated. “These discussions include a possible license for Africa.” Aspen stated that the sales of its Covid-19 vaccination started in the third quarter of the company’s fiscal year and produced revenue of around R400 million; however, the company did not disclose the margin on the jabs.
Is Aspen a private company?
Botswana is one of the key countries. Kenya Namibia Africa, South Tanzania For the MAT period beginning in July 2020, the private pharmaceutical industry in South Africa was estimated to be worth R45.4 billion. Products manufactured by Aspen and Ethicare accounted for four of the top ten most valuable brands in the private sector in South Africa.
Who started Aspen Pharmaceuticals?
Aspen Pharmacare, the most successful medicines manufacturer in South Africa, was established by Stephen Saad in 1997.
Is Aspen an international company?
Aspen is a global specialized and branded multinational pharmaceutical firm that has been around for more than 160 years. The company has a presence in both developing and established countries across the world. Our high-quality, cost-effective products are used to enhance the health of patients in over 150 countries, and we have roughly 9,800 people working across 71 locations located in over 50 countries.
Aspen’s primary business sectors allow us to concentrate on the development, production, and distribution of a comprehensive selection of post-patent, branded, and domestically produced pharmaceuticals, serving both the hospital and consumer markets. Manufacturing and Commercial Pharmaceuticals are the two most important parts of this company’s business, and they include Sterile Focus Brands and Regional Brands.
Anaesthetics and Thrombosis medicines are also included in this category.
What does Aspen Pharmacare do?
The largest pharmaceutical firm in Africa is owned and operated by Aspen Pharmacare Holdings Limited, a South African multinational holding company that specializes in the pharmaceutical industry.
When did Aspen Pharmacare go public?
| Aspen Holdings Head Office, Umhlanga, South Africa | |
| Type | Public ( JSE : APN ) JSE Limited |
|---|---|
| Industry | Health care , Pharmaceutical industry |
| Predecessor | Lennon Ltd |
| Founded | 1850, public 1997. |
| Headquarters | La Lucia Ridge , Umhlanga , South Africa |
| Key people | Stephen Saad (Group Chief Executive), Gus Attridge (Deputy Group Chief Executive) |
| Products | Specialty branded pharmaceuticals , injectables , tablets , liquids, capsules , steriles, biologicals, active ingredients , nutritional products |
| Revenue | R 42,596,000,000 ( FY 2018 ) |
| Net income | R 8,288,000,000 ( FY 2018 ) |
| Total assets | R 132,836,000,000 ( FY 2018 ) |
| Total equity | R 50,095,000,000 ( FY 2018 ) |
| Owner | JSE Listed |
| Number of employees | 9,100 |
| Website | www . aspenpharma . com |
Aspen Pharmacare Holdings Limited is an international pharmaceutical firm that was established in 1850 in South Africa. It has become the largest pharmaceuticals company in Africa through a strategy of aggressive mergers and expansion. As of the year 2022, the majority of the company’s income comes from the sale of commercial generic medications (74%) while the production of drugs accounts for just 26%.
Who is Aspen?
ABOUT ASPEN We are a worldwide speciality and branded pharmaceutical business with our headquarters in Durban, South Africa. Our mission is to improve the health of people all over the globe by providing medications that are of the highest quality and are also affordable.
What is Aspen rxhealth’s technology?
The value that the connection between a patient and a pharmacist holds is being rethought because to innovative technologies developed by Aspen RxHealth. The new mobile application makes it far simpler than ever before for health plans and risk-bearing providers to create individualized outreach strategies linking their members to the largest network of on-demand pharmacists in the country.